What began as a routine adjustment in a patient’s COPD management quickly evolved into a complex and unexpected medical case that is now drawing attention from clinicians and researchers alike. In just under 48 hours, a 55-year-old woman developed intensely painful, bright red patches across her face and neck—symptoms that initially appeared alarming but not entirely uncommon in dermatological practice. However, what followed challenged conventional understanding and may expand current knowledge about medication-related immune reactions.
The patient, who had a known history of Chronic Obstructive Pulmonary Disease and hypertension, had been stable for years on a treatment plan that included enalapril and a long-acting bronchodilator inhaler containing formoterol. Due to a recent decline in lung function, her pulmonologist decided to switch her inhaler to a newer combination therapy consisting of indacaterol and glycopyrronium—both commonly used medications in the long-term management of COPD.
At first, nothing seemed unusual. The patient began using the new inhaler as prescribed, expecting improved breathing and symptom control. However, within two days, she noticed the sudden appearance of painful, erythematous plaques spreading across her face and neck. The lesions were vivid in color, sharply defined, and associated with tenderness that made even light touch uncomfortable. Alongside these skin changes, she developed a low-grade fever, further complicating the clinical picture.
Concerned by the rapid progression of symptoms, the patient sought medical attention. She denied any recent changes in skincare products, diet, or exposure to allergens. Although she mentioned recent sun exposure, she had used appropriate protection, making photosensitivity less likely as a primary cause. With no obvious external triggers identified, clinicians began to suspect a deeper, systemic issue.
She was promptly referred to dermatology, where specialists conducted a thorough evaluation. The first step was to discontinue the newly introduced inhaler, given the temporal relationship between the medication change and symptom onset. Blood tests were ordered to rule out infections, autoimmune diseases, and other inflammatory conditions. Results showed no clear signs of infection or underlying autoimmune disorder, narrowing the list of possible diagnoses.
